UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices) (Zip code)
Registrant’s telephone number, including area code:
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.07 | Submission of Matters to a Vote of Security Holders. |
On June 10, 2026, Cytek Biosciences, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). Of the 129,142,587 shares of the Company’s common stock outstanding as of the close of business on the record date of April 13, 2026, 111,161,490 shares were either present at the virtual meeting or represented by proxy, constituting approximately 86.1% of the outstanding shares of common stock entitled to vote. The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below:
| 1. | Election of Class II Directors. Each of the following nominees was elected to serve as a Class II director, to hold office until the Company’s 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified or until his or her earlier death, resignation or removal, based on the following results of voting: |
| Nominee | Votes For | Votes Withheld | Broker Non-Votes | |||||||||
| Vera Imper, Ph.D. |
64,769,976 | 20,723,477 | 25,668,037 | |||||||||
| Glenn P. Muir |
79,599,103 | 5,894,350 | 25,668,037 | |||||||||
| Ming Yan, Ph.D. |
76,741,063 | 8,752,390 | 25,668,037 | |||||||||
| 2. | Executive Compensation. On a non-binding, advisory basis, the compensation paid to the Company’s named executive officers for the year ended December 31, 2025 was approved based on the following results of voting: |
| Votes For | Votes Against | Abstentions | Broker Non-Votes | |||
| 84,794,380 | 677,861 | 21,212 | 25,668,037 |
| 3. | Ratification of the Selection of Independent Registered Public Accounting Firm. The selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based on the following results of voting: |
| Votes For | Votes Against | Abstentions | Broker Non-Votes | |||
| 110,533,253 | 479,883 | 148,354 | — |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Cytek Biosciences, Inc. | ||||||
| Date: June 16, 2026 | By: | /s/ Wenbin Jiang, Ph.D. | ||||
| Wenbin Jiang, Ph.D. | ||||||
| President and Chief Executive Officer | ||||||